SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that all shareholding members of its board of directors and management have, subject to certain exceptions, signed lock-up agreements for their shares and/or other securities in the company until and including December 31, 2026.
The members of SynAct's management and the board of directors listed below have, subject to certain exceptions, committed through so-called lock-up undertakings not to sell (or otherwise make certain transactions with similar effect) their shares and/or other securities in SynAct, held directly or indirectly through wholly owned entities, during the period until and including December 31, 2026.
“SynAct Pharma is entering into an important phase with full focus on business development and further development of our dengue virus and viral infections projects. The Board’s decision to enter lock-up agreements signals our firm belief in the company’s potential towards strategic partnerships,” said Anders Kronborg, Chairman of the Board of Directors, SynAct Pharma.
“This decision demonstrates our unwavering commitment to SynAct Pharma’s strategy and to our shareholders this lock-up shows that management strongly believes in the company’s future and stands fully behind its trajectory,” said Jeppe Øvlesen, CEO.
The following members of the board of directors and the management with current shareholding have signed lock-up agreements:
- Jeppe Øvlesen, CEO
- Mads Liebach Bjerregaard, CBO
- Thomas Jonassen, CSO
- Thomas Boesen, COO
- Ann Kristin Led, CFO
- Anders Kronborg, Chairman of the Board
- Sten Scheibye, Board Member
- Sten R Sörensen, Board Member
- Jeppe Ragnar Andersen, Board Member